Vertex sets Nov. 30 PDUFA for povetacicept
Vertex Pharmaceuticals set a Nov. 30 Prescription Drug User Fee Act target date for povetacicept in IgA nephropathy, citing phase data showing a 52% UPCR drop and biomarker gains.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.